source
- Human‑centric testing methods promise safer, cheaper drug development but repeatability remains a key obstacleRegulators such as the FDA, EMA and ICH are urging drug developers to replace animal safety studies with New Approach Methodologies that use human‑relevant models. Early research shows these models…
- Roivant's FcRn drug IMVT-1402 fails Phase 2b lupus trialRoivant announced that its FcRn-targeting antibody IMVT-1402 (imeroprubart) failed to meet primary endpoints in a Phase 2b trial in patients with lupus. The study did not show improvement in disea…